West Pharmaceutical Servs Analyst Price Targets

PRO

なぜ動いているのか？:West Pharmaceutical Services shares are trading higher after the company re...

配当金: 配当落ち日は13 日後です。

決算: 今日Q3 2026決算発表マーケットオープン前でした。

決算説明会: 本日の電話会議は19 時間前開始しました。

クリックしてウェブキャストを見る

West Pharmaceutical Servs Analyst Price Targets

Wall Street analyst price targets and consensus rating for West Pharmaceutical Servs (WST).

Price Target Range — 10 Quarters

Analyst Consensus — 13 Analysts

13Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$405Upside to Avg. PT-2.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$410→$420
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$400→$440
Sep 22, 2026	Morgan Stanley	Kallum Titchmarsh	Upgrade	Equal-Weight→Overweight	$365→$400
Sep 9, 2026	UBS	Doug Schenkel	PT Raise	Buy	$340→$415
Aug 3, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$400→$412
Jul 27, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$410→$425
Jul 13, 2026	BNP Paribas	Curtis Moiles	Initiate	Outperform	$447
Jul 9, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Equal-Weight	$325→$365
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$390→$410
Jul 2, 2026	Keybanc	Paul Knight	PT Raise	Overweight	$350→$390
Jun 9, 2026	Barclays	Luke Sergott	Upgrade	Equal-Weight→Overweight	$310→$400
Jun 2, 2026	Stephens & Co.	Steven Etoch	Maintained	Overweight	$360
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Outperform	—
May 29, 2026	Morgan Stanley	Kallum Titchmarsh	PT Raise	Equal-Weight	$315→$325
Apr 27, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$275→$310
Apr 14, 2026	Barclays	Luke Sergott	PT Raise	Equal-Weight	$265→$275
Feb 13, 2026	Barclays	Luke Sergott	PT Cut	Equal-Weight	$325→$265
Feb 3, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$390→$320
Dec 2, 2025	Morgan Stanley	Kallum Titchmarsh	Initiate	Equal-Weight	$285
Oct 29, 2025	TD Cowen	Brendan Smith	Initiate	Buy	$350

Analyst Ratings News

This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History

Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.

Piero Cingari

PRO
CNBC Halftime Report Final Trades: JP Morgan Chase & Co., Meta Platforms, West Pharmaceutical Services, iShares U.S. Energy ETF

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420

TD Cowen analyst Brendan Smith maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $410 to $420.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $400 to $440.

Benzinga Newsdesk

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

Benzinga Newsdesk

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.

Benzinga Newsdesk

West Pharmaceutical Services Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

West Pharmaceutical Servs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History

PRO
CNBC Halftime Report Final Trades: JP Morgan Chase & Co., Meta Platforms, West Pharmaceutical Services, iShares U.S. Energy ETF

PRO
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

People Also Watch

People Also Watch

West Pharmaceutical Services Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

West Pharmaceutical Servs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History

PROCNBC Halftime Report Final Trades: JP Morgan Chase & Co., Meta Platforms, West Pharmaceutical Services, iShares U.S. Energy ETF

PROTD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420

PROBarclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PROLive On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PROMorgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

People Also Watch

People Also Watch

PRO
CNBC Halftime Report Final Trades: JP Morgan Chase & Co., Meta Platforms, West Pharmaceutical Services, iShares U.S. Energy ETF

PRO
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420

PRO
Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

PRO
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: West Pharmaceutical Services"

PRO
Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400